Neuralink Brings Blindsight Brain Implant Trials to UAE in World First

FREMONT, Calif. — Neuralink is set to conduct the world's first human implantation of its Blindsight brain-computer interface outside the United States, partnering with Cleveland Clinic Abu Dhabi to begin the UAE-PRIME trial in 2026. The program marks a significant expansion of Neuralink's global clinical footprint and brings the company's most ambitious technology — restoring vision to people who are completely blind — into active human testing.

The Blindsight device, which received FDA Breakthrough Device Designation in September 2024, works by bypassing damaged or absent optic nerves entirely and delivering visual signals directly to the brain's visual cortex through precisely targeted electrical stimulation. Unlike prior visual prosthetics that required functioning retinal tissue, Blindsight's cortical approach means it could theoretically restore some form of sight even in patients who were born without functional vision.

The UAE-PRIME Trial

The UAE-PRIME trial is modeled on Neuralink's U.S.-based PRIME study, which has enrolled patients with paralysis and demonstrated that implanted participants can control digital interfaces — including computer cursors and robotic limbs — using only their thoughts. UAE-PRIME extends that research infrastructure to Abu Dhabi, where Cleveland Clinic Abu Dhabi provides world-class neurology and neurosurgery capabilities alongside patient access across the broader Gulf region.

Collaborating with an internationally recognized medical institution gives Neuralink access to a diverse patient population while the Blindsight device awaits separate FDA approval for U.S. vision trials. The UAE regulatory environment allowed Neuralink to initiate human testing without waiting for the domestic pathway to clear — a common and accepted approach for companies holding FDA Breakthrough status.

How the Technology Works

The Blindsight chip is implanted into the visual cortex, located at the rear of the brain. Small electrode arrays stimulate neurons in precise spatial patterns, creating phosphene sensations — points or shapes of perceived light — that combine into a rudimentary but functional representation of the visual environment. Early-generation Blindsight outputs are expected to resemble low-resolution images rather than natural sight, with improvements expected as electrode density and signal processing algorithms advance over successive device generations.

Elon Musk has stated publicly that the visual cortex retains its underlying structure even in individuals who have been blind from birth, and that stimulating it could produce meaningful visual experiences even for those who have never seen before. Clinical data from UAE-PRIME will test that hypothesis directly, providing the first real-world evidence for or against the approach.

A Growing Clinical Program

Neuralink now has 21 patients implanted with its Telepathy device in the United States across the PRIME and CONVOY studies. The CONVOY trial is investigating brain-controlled robotic limbs, representing a progression from digital communication to physical manipulation. One PRIME participant has already transitioned into the CONVOY study, demonstrating how Neuralink's technology can build on itself.

Looking further ahead, Neuralink has opened a global patient registry for individuals interested in future trials, including Blindsight, and the company aims to conduct up to 20,000 neurochip surgeries annually by 2031. If Blindsight's UAE results validate the cortical stimulation approach, the pathway toward restoring sight for millions of people with visual impairment becomes considerably shorter.